Healthcare | May 16, 2022
New report highlights lack of access to assistive technology
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Subscribe To Our Newsletter & Stay Updated
